Accessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

ImmunityBio Boosts Outlook with Strong Revenue Growth and Clinical Advances

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 11/30/2025, 11:12 am ET | 6 min
ImmunityBio Boosts Outlook with Strong Revenue Growth and Clinical Advances Thumbnail

In this article Last trade Nov, 28 4:59 PM

  • IBRX+12.68%
    IBRX - NYSEImmunityBio Inc.
    $2.40+0.27 (+12.68%)
    Volume:  22.28M
    Float:  300.61M
    $2.15Day Low/High$2.45

ImmunityBio Inc. stocks have been trading up by 12.68 percent amid FDA breakthrough designation and positive clinical developments.

Healthcare industry expert:

Analyst sentiment – positive

As an expert in the healthcare industry, my assessment of ImmunityBio (IBRX) indicates a tenuous market position reflected by significant net losses and negative profitability margins across the board. Despite a gross margin of 99.6%, the exorbitant EBIT margin of -319.5% and pretax profit margin of -2322.8% underscore substantial inefficiencies and a precarious operating scene. IBRX’s valuation metrics show troubling valuations, with price-to-book at -4.43 and an enterprise value indicating heavy market speculation. Cash flow analyses reveal negative free cash flow, substantial cash use by investing activities, and an increasing reliance on financing, suggesting potential challenges in sustaining operations.

In analyzing IBRX’s recent weekly trading data, there are definite short-term bullish signals, with the stock price showing higher closing levels in recent sessions. The dominant trend appears to be upward, driven predominantly by accumulated buying pressure. For a trading strategy, practitioners should look for support at the $2.05 mark, which represents recent lows, while observing resistance near $2.40. A break above this level with confirmed volume could signal further bullish momentum, while failure to sustain price action above $2.16 might suggest a re-entry into a consolidation phase.

Looking ahead, IBRX’s recent developments and clinical trials in niche oncology markets, such as glioblastoma and non-small cell lung cancer, provide potential growth catalysts. The company’s substantial sales growth, marked by a reported increase to $75 million for ANKTIVA, aligns favorably with a sector-wide shift toward immunotherapies. With ImmunityBio’s strong position in innovative treatment solutions and its impressive cash reserves, the outlook appears substantially positive. The stock’s ability to surpass a psychological resistance level at $2.40 could underline strategic growth milestones, setting an implied target range of $3.00, contingent on the adherence to favorable clinical outcomes and ongoing expansion efforts.

  • ImmunityBio has reported an impressive 467% growth in unit sales year-to-date for 2025, translating into $75M in revenue. This marks a significant milestone indicating robust demand for its flagship product ANKTIVA.

  • The company has announced positive clinical trial results for various cancer treatments, including glioblastoma and non-small cell lung cancer (NSCLC). These findings have facilitated the commencement of significant studies aimed at further proving ANKTIVA’s efficacy.

  • The Q3 EPS report reveals a loss of 7 cents, yet this surpasses consensus estimates by 4 cents. Additionally, the addition of ANKTIVA as a preferred drug by a major medication contracting organization highlights its growing acceptance in the market.

Candlestick Chart

Weekly Update Nov 24 – Nov 28, 2025: On Sunday, November 30, 2025 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 12.68%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ImmunityBio’s financial health reflects a mixed bag of high growth and ongoing challenges. The company has achieved a noteworthy 467% increase in its unit sales, pushing its revenues to touch the $75M mark for the year 2025. Despite this revenue surge, the bottom line indicates continued hurdles, as evidenced by an EBITDA of -$51M and a net income loss of $67M for Q3 2025. The company also boasts a healthy cash flow, with ending cash at $60M, despite a significant cash outflow for investment activities.

Additionally, profitability ratios are not favorable at this stage, with an EBIT margin of -319.5% and a pretax profit margin of -2322.8%. This is reflective of the ongoing heavy investments in R&D to support the company’s long-term strategic plans. ImmunityBio’s current ratio stands strong at 5.8, suggesting the company is well-positioned to meet its short-term liabilities, crucial for its stability amidst the high cash burn for research efforts.

More Breaking News

The stock’s trading volume has been volatile, with recent highs observed at $2.16 and lows at $2.05, indicating active trading amidst the promising outlook yet ongoing financial challenges. This mirrors investor interest fueled by significant growth milestones and the prospects of future profitability as clinical advancements continue to reshape the company’s potential market positioning.

Conclusion

ImmunityBio stands at a pivotal juncture, as evidenced by its remarkable sales achievements and ambitious clinical endeavors. Driven by patient demand for less invasive, more effective treatments, the company has solidified its standing as a leader in immunotherapy solutions with broad oncological applications. However, whilst the fundamental indicators convey strength in strategic execution and market expansion, financial statements suggest the journey to profitability is interlaced with complexities inherent to biotech investments.

Traders keen on ImmunityBio should weigh the immediate pressures of high financial leverage against the backdrop of a promising oncology pipeline poised for regulatory milestones and commercial viability. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” As new partnerships and broader market integrations unfold, stock vigilantes stand poised to capture momentum driven by both macro trends in health sciences and ImmunityBio’s intrinsic tactical excellence.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

In this article (YTD Performance)

  • IBRX-7.81%
    IBRX - NYSEImmunityBio Inc.
    $2.40+0.27 (+12.68%)
    Volume:  22.28M
    Float:  300.61M
    $2.15Day Low/High$2.45

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Learn The Formula That Has Created Over 50 Millionaires
TRADE LIKE TIM
notification icon
Subscribe to receive notifications